Bazedoxifene/conjugated estrogens

Bazedoxifene/conjugated estrogens
Combination of
Bazedoxifene Selective estrogen receptor modulator
Conjugated estrogens Estrogen
Clinical data
Trade names Duavee
Routes of
administration		 By mouth
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • None

The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis. It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer.

Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet. Pfizer expects the drug to become available in the first quarter of 2014.[1]

See also

References

  1. ↑ https://www.wsj.com/article/PR-CO-20131003-910561.html



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.